Navigation Links
CHERISH trial demonstrates efficacy of tocilizumab in juvenile idiopathic arthritis
Date:6/12/2013

Madrid, Spain, 12 June 2013: A new study presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism shows that tocilizumab is efficacious and leads to a sustained clinically meaningful improvement in children with polyarticular Juvenile Idiopathic Arthritis (pcJIA).

Tocilizumab is a humanized recombinant antibody, which blocks the receptors where interleukin-6 (IL-6) attaches to the surface of cells. When IL-6 is unable to attach to these cells, they are prevented from driving inflammation. Elevated serum and joint fluid IL-6 levels have been shown to be associated with disease activity in patients with pcJIA.1

"JIA is a chronic arthritis occurring in 1 in every 1,000 children. With no known cause, it can lead to joint damage and permanent disability. These data show that tocilizumab rapidly improves signs and symptoms of pcJIA, with meaningful clinical responses maintained in a large proportion of patients at week 40," said lead author Dr. Fabrizio De Benedetti of the IRCCS Ospedale Pediatrico Bambino Gesu, Rome.

Speaking on behalf of the Paediatric Rheumatology International Trials Organisation (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG), who had overseen this study, Dr. De Benedetti concluded that "these data suggest that tocilizumab is going to be a novel biologic part of the therapeutic armamentarium for pcJIA."

CHERISH is a two-year, 3-part trial being conducted at 58 centres across 15 countries. Patients aged 2-17 years were included in the study if they had active pcJIA for at least 6 months and had failed to respond to methotrexate (a cornerstone of therapy worldwide for this condition).

Part 1 of the study was a 16-week open-label phase in which 188 patients received tocilizumab every four weeks. The 166 patients who achieved at least a 30% improvement in symptoms and signs of pcJIA (an JIA ACR30* response) went on to part 2, which was a 24-week
'/>"/>

Contact: EULAR Press Office
eularpressoffice@cohnwolfe.com
44-020-733-15364
European League Against Rheumatism
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Brain Tumor Vaccine Shows Promise in Early Trial
2. URMC clinical trial tests new regimen for hypertension
3. Analysis Finds Clinical Trials Often Small, of Poor Quality
4. US spends far more for health care than 12 industrialized nations, but quality varies
5. New Weight-Loss Drug Shows Promise in Trial
6. Palpitations are predictive of future atrial fibrillation
7. Trial Set to See if Drug Can Prevent Alzheimers
8. Experts call for clinical trials to test non-skeletal benefits of vitamin D
9. Breast cancer clinical trial tests combo of heat shock protein inhibitor and hormonal therapy
10. Canada should significantly increase its funding of randomized clinical trials
11. Alzheimers vaccine trial a success
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... This report studies the global pharmacovigilance and drug ... 2014 to 2019. This market is expected to ... to 2019. , Further Inquiry @ http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=16831714 ... and drug safety software market has been classified ... namely, adverse event reporting software, drug safety audits ...
(Date:3/30/2015)... New York, New York (PRWEB) March 30, 2015 ... of its Top 10 Exotic Water Awards, with the top ... other winners are listed on the company’s website, along with ... Water’s website, exotic water, glacial water, spring water, mineral water ... Fiji water is one of the top exotic water ...
(Date:3/30/2015)... FMC Corporation’s Health and Nutrition division ... Epax® Ultra and Core concentrates manufactured in the ... ensures the manufacturing process and all physical raw ... for Halal. , The new Halal certification ... advance its customer service to a global market ...
(Date:3/30/2015)... Slidezilla, an app from the makers of ... innovates the fun and simplicity of photo slideshows. The ... slideshows and then instantly share them across their Facebook, ... to create a slideshow app where users can share ... options to personalize them. You can choose your own ...
(Date:3/30/2015)... V/NO (Virtually No Alcohol) Wines have a sleek ... and for reuse. Consumers simply twist the cup, turn it ... professionals, and basically anyone can now enjoy a non-alcoholic ... socially or pair with meals at work, home, or wherever ... and that means Napa Wine grapes undergo the traditional ...
Breaking Medicine News(10 mins):Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 2Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 3Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 4Health News:Best Exotic Water Brands Acclaimed by 10 Best Water 2Health News:FMC Health and Nutrition Announces Halal Certification for Epax® Brand Omega-3 Ingredients 2Health News:Napa Valley Alcohol-Removed Red, White & Rosé Wines Have Launched. 2
... CAWhen cells find themselves in a tight spot, the ... cells time to repair the damage, or if all ... to other stress-induced genes, which dispense with the regular ... factor that also helps with the editing of transcripts, ...
... Loyola University Health System study includes some unexpected ... Contrary to expectations, patients who died from their ... than patients who survived., "Perhaps a better understanding ... for therapies that further improve outcomes in burn ...
... CAWhen cells find themselves in a tight spot, the ... cells time to repair the damage, or if all ... to other stress-induced genes, which dispense with the regular ... factor that also helps with the editing of transcripts, ...
... children and adolescents. In the current issue of ... 173-79), Susanne Walitza and her colleagues point out that ... course of the disease. Compulsive washing, the most ... in up to 87% of all patients; other common ...
... The United States should pay close attention to how the ... worth using factors that go beyond clinical and cost effectiveness, ... Bioethics. In a commentary to appear in the April ... , the bioethicists detail and discuss a new, "value-based pricing" ...
... establishes a unique system to perform in vivo ... networks that regulate hepatocyte proliferation during chronic liver ... that stable knockdown of the candidate gene by ... of mouse hepatocytes and also increase the regenerative ...
Cached Medicine News:Health News:'SKIP'-ing splicing forces tumor cells to undergo programmed cell death 2Health News:'SKIP'-ing splicing forces tumor cells to undergo programmed cell death 3Health News:Surprising finding from smoke inhalation study 2Health News:‘SKIP’-ing splicing forces tumor cells to undergo programmed cell death 2Health News:‘SKIP’-ing splicing forces tumor cells to undergo programmed cell death 3Health News:Placing value, price on new drugs: The challenge facing new UK policy, say Hopkins bioethicists 2Health News:Placing value, price on new drugs: The challenge facing new UK policy, say Hopkins bioethicists 3
(Date:3/30/2015)... March 30, 2015   GlassesUSA , the online retailer ... $12.5 million in new financing led by Viola Private ... will further GlassesUSA,s aggressive business growth and accelerate their expansion ... online eyewear, both B2C and B2B. GlassesUSA was ... Eldad Rothman , and CTO Roy Yamner . ...
(Date:3/30/2015)... HA,AYIN, Israel , March 30, 2015 ... of Dr. Yuval Avni as the company,s ... partner at Giza VC, a leading early stage Israeli ... with clinical experience in general and vascular surgery.   ... company also announced today that Sherpa Innoventures is Beta-O2,s ...
(Date:3/30/2015)... Pharmaceuticals Corporation (NASDAQ: RXII ), a biotechnology ... primarily in the areas of dermatology and ophthalmology ... financial results for the fourth quarter and year ... update. Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ... a steady growth and evolution for RXi Pharmaceuticals," ...
Breaking Medicine Technology:GlassesUSA.com Raises $12.5 Million Growth Round Led By Viola Private Equity 2GlassesUSA.com Raises $12.5 Million Growth Round Led By Viola Private Equity 3Beta-O2 Names Dr. Yuval Avni CEO 2Beta-O2 Names Dr. Yuval Avni CEO 3RXi Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results and Recent Corporate Highlights 2RXi Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results and Recent Corporate Highlights 3RXi Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results and Recent Corporate Highlights 4RXi Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results and Recent Corporate Highlights 5RXi Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results and Recent Corporate Highlights 6RXi Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results and Recent Corporate Highlights 7RXi Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results and Recent Corporate Highlights 8RXi Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results and Recent Corporate Highlights 9RXi Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results and Recent Corporate Highlights 10
... Thoratec Corporation (NASDAQ: THOR ), a ... to save, support and restore failing hearts, today ... relating to WiTricity,s proprietary wireless resonant energy transfer ... circulatory support. Through a collaborative effort ...
... OMER ), a biopharmaceutical company committed to ... and disorders of the central nervous system, today announced ... Financial ResultsTotal operating expenses for the ... compared to $6.8 million for the same periods in ...
Cached Medicine Technology:Thoratec Announces Development Agreement With WiTricity for Proprietary Energy Transfer Technology 2Thoratec Announces Development Agreement With WiTricity for Proprietary Energy Transfer Technology 3Thoratec Announces Development Agreement With WiTricity for Proprietary Energy Transfer Technology 4Omeros Corporation Reports First Quarter 2011 Financial Results 2Omeros Corporation Reports First Quarter 2011 Financial Results 3Omeros Corporation Reports First Quarter 2011 Financial Results 4
The ImagingPlanet 80 mm surgical microscope video adapter: superior optical quality and precise engineering make this 80 mm focal length adapter an excellent decision for use with your Leica surgical...
The ImagingPlanet 80 mm Surgical Microscope Adapter. Superior optical quality and precise engineering make this 80 mm focal length adapter an excellent decision for use with your Zeiss surgical micro...
The ImagingPlanet 55 mm Surgical Microscope Adapter. Superior optical quality and precise engineering make this 55mm focal length adapter an excellent decision for use with your Zeiss surgical micro...
The ImagingPlanet 70 mm Surgical Microscope Adapter. Superior optical quality and precise engineering make this 70 mm focal length adapter an excellent decision for use with your Leica surgical micr...
Medicine Products: